Global hunt for answers on new bladder cancer drug duo
NCT ID NCT07420855
Summary
This study is looking back at the real-world results of a two-drug combination (enfortumab vedotin plus pembrolizumab) used as the first treatment for people with advanced bladder cancer that has spread. It aims to collect information from around the world to see how long patients live and how long the cancer stays controlled. The study will also track side effects and how many patients' tumors shrink.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ospedale di Macerata
Macerata, 62100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.